Neurology & CNS Deal Benchmarks
Deal benchmarks for Alzheimer's, Parkinson's, epilepsy, migraine, schizophrenia, and other neurological disorders. Benchmarks derived from 135 verified transactions.
135
Total Deals
$913M
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
43
license
36
acquisition
25
collaboration
9
option
9
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Neurona Therapeutics → UCB NRTX-1001 | acquisition | $650M | $1.1B | Apr 2026 |
Haisco Pharmaceutical Group → AbbVie HSK55718 and HSK51155 | license | $30M | $745M | Apr 2026 |
AC Immune SA → Eli Lilly and Company Morphomer Tau | license | $10M | $1.7B | Apr 2026 |
Centessa Pharmaceuticals → Eli Lilly Cleminorexton (ORX750) — full company acquisition | acquisition | $6.3B | $7.8B | Mar 2026 |
Apnimed → Shionogi Shionogi-Apnimed Sleep Science (SASS) joint venture stake | acquisition | $100M | $150M | Mar 2026 |
Alteogen Inc. → Biogen Inc. ALT-B4 | license | $20M | $579M | Mar 2026 |
Corium Therapeutics → Collegium Pharmaceutical Azstarys | acquisition | $650M | $785M | Mar 2026 |
Sangamo Therapeutics → Eli Lilly STAC-BBB AAV capsid | license | $18M | $1.4B | Mar 2026 |
Verve Therapeutics → Eli Lilly neurological gene-editing therapies | acquisition | $1.3B | $1.3B | Mar 2026 |
Zevra Therapeutics → Commave Therapeutics SA serdexmethylphenidate (SDX) portfolio | acquisition | $50M | $50M | Mar 2026 |
Benchmark Your Neurology & CNS Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 135 verified neurology & cns transactions.
Run Neurology & CNS Benchmark